.jpeg)
2026-08-12 04:11:20
Enasidenib (brand name IDHIFA) is an oral, selective IDH2 inhibitor indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH2 mutation. This article covers its indications, dosing, adverse effects, mechanism of action, storage, and special-population considerations.
2026-08-11 06:06:06
Midostaurin and gilteritinib are both FLT3-targeted agents but differ fundamentally in selectivity, indications, and treatment phase. This article systematically compares their mechanisms, clinical roles, and appropriate use contexts in precision AML management.
2026-08-11 05:57:10
Lapatinib is an oral small-molecule tyrosine kinase inhibitor targeting HER2 and EGFR pathways in HER2-positive breast cancer. This article clarifies its therapeutic positioning, clinical applications, and the critical role of HER2 testing in treatment decisions.
2026-08-11 05:29:21
Filgotinib is an oral selective JAK1 inhibitor used for rheumatoid arthritis and ulcerative colitis. This article explains its targeted immune-modulating mechanism, therapeutic advantages, and key safety considerations for long-term use.
2026-08-11 05:22:22
Lapatinib is an oral HER2-targeted anticancer agent. This article covers dosing schedule, food interactions, combination regimens, missed-dose management, drug interactions, and safety monitoring for patients with HER2-positive breast cancer.
2026-08-10 07:50:50
Capivasertib (Truqap) is the first-in-class selective AKT inhibitor approved in combination with fulvestrant for HR-positive, HER2-negative advanced breast cancer harboring PIK3CA/AKT1/PTEN alterations. This guide covers indications, recommended dosing, special populations, warnings, drug interactions, and adverse event management.
2026-08-10 07:34:19
Cemiplimab is a PD-1 immunotherapy drug used for advanced skin cancers and non-small cell lung cancer. As a biologic agent, it requires strict refrigeration at 2°C to 8°C, protection from freezing, light, and agitation to maintain drug stability and efficacy.
2026-08-10 07:19:45
At the 62nd ASCO Annual Meeting, targeted therapies, ADCs and immunotherapies advanced on three fronts against pancreatic cancer. Phanes Therapeutics' CLDN18.2/CD47 bispecific antibody spevatamig, combined with GnP chemotherapy, showed striking first-line data in metastatic pancreatic cancer, and its innate immunity–enhancing mechanism may break the "cold tumor" dilemma.
2026-08-10 06:59:18
On August 6, 2026, Moderna’s mRNA seasonal influenza vaccine mFLUSIVA became the first mRNA flu vaccine approved by the U.S. FDA for adults aged 50 and older, ushering in a new era of mRNA-based influenza prevention.
2026-08-10 06:51:08
Nintedanib (Ofev) is a multi-target antifibrotic agent approved for IPF, progressive fibrosing interstitial lung diseases, and systemic sclerosis-associated ILD. This article outlines its full therapeutic scope and mechanism of action.
2026-08-10 06:39:28
Belumosudil (Rezurock) is a selective ROCK2 inhibitor approved for chronic graft-versus-host disease. This article explains the expected timeline, efficacy assessment, and realistic goals when treating pulmonary cGVHD.
2026-08-07 07:30:56
Mavacamten is the first cardiac myosin inhibitor targeting the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM). This article reviews its treatment duration, clinical efficacy, head-to-head comparisons with conventional therapies, and long-term management strategies.
